drugset / Trial / NCT01860482

The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD

NCT01860482

Phase 4 Completed 39 enrolled Chong Kun Dang Pharmaceutical
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in patients with refractory reflux esophagitis to the prior standard PPIs regimen.

Timeline

Start
2013-04
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Rabeprazole Small molecule 10 mg Oral

Indications